Department of General Surgery and Surgical Specialties, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.
UOC of General and Minimally Invasive Surgery, Hospital "San Paolo", Largo Donatori del Sangue 1, 00053, Civitavecchia, Rome, Italy.
J Endocrinol Invest. 2023 Aug;46(8):1589-1596. doi: 10.1007/s40618-023-02013-7. Epub 2023 Jan 27.
Minimally invasive surgery is the gold standard treatment for adrenal masses, but it may be a challenging procedure in the case of pheochromocytoma (PHEO). The aim of the present study is to report the results of transperitoneal laparoscopic adrenalectomy (TLA) in cases of PHEO in comparison to other types of adrenal lesions.
From 1994 to 2021, 629 patients underwent adrenalectomy. Twenty-two and thirty-five patients, respectively, were excluded because they underwent bilateral and open adrenalectomy, leaving 572 patients for inclusion. Of these, 114 patients had PHEO (Group A), and 458 had other types of lesions (Group B). To adjust for potential baseline confounders, a propensity score matching (PSM) analysis was conducted.
After PSM, 114 matched pairs of patients were identified from each group. Statistically significant differences were not observed when comparing the median operative time (85 and 90 min in Groups A and B, respectively, p = 0.627), conversion rate [6 (5.3%) in each group, p = 1.000], transfusion rate [4 (3.5%) and 3 (2.6%) in Groups A and B, respectively, p = 1.000], complication rate [7 (6.1%) and 9 (7.9%) in Groups A and B, respectively, p = 0.796), median postoperative hospital stay (3.9 and 3.6 days in Groups A and B, respectively, p = 0.110), and mortality rate [1 (0.9%) in each group, p = 1.000].
Based on this analysis, the results of TLA for PHEO are equivalent to those of TLA for other types of adrenal lesions, but the fundamental requirements are multidisciplinary patient management and adequate surgeon experience. Further prospective studies are required to draw definitive conclusions.
微创外科是治疗肾上腺肿块的金标准,但对于嗜铬细胞瘤(PHEO),这可能是一项具有挑战性的手术。本研究旨在报告经腹腔腹腔镜肾上腺切除术(TLA)治疗 PHEO 的结果,并与其他类型的肾上腺病变进行比较。
1994 年至 2021 年,共有 629 例患者接受了肾上腺切除术。由于双侧和开放性肾上腺切除术,分别排除了 22 例和 35 例患者,最终纳入了 572 例患者。其中,114 例患者患有 PHEO(A 组),458 例患者患有其他类型病变(B 组)。为了调整潜在的基线混杂因素,进行了倾向评分匹配(PSM)分析。
PSM 后,每组分别确定了 114 对匹配的患者。比较两组患者的中位手术时间(A 组和 B 组分别为 85 分钟和 90 分钟,p=0.627)、转化率[每组各有 6 例(5.3%),p=1.000]、输血率[A 组和 B 组分别有 4 例(3.5%)和 3 例(2.6%),p=1.000]、并发症发生率[A 组和 B 组分别有 7 例(6.1%)和 9 例(7.9%),p=0.796]、中位术后住院时间[A 组和 B 组分别为 3.9 天和 3.6 天,p=0.110]和死亡率[每组各有 1 例(0.9%),p=1.000]均无统计学差异。
基于本分析,TLA 治疗 PHEO 的结果与 TLA 治疗其他类型肾上腺病变的结果相当,但基本要求是多学科患者管理和充足的外科医生经验。需要进一步的前瞻性研究来得出明确的结论。